Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

1 Stock To Buy, 1 To Dump When Markets Open: Jabil, Vertex Pharmaceuticals

By Investing.com (Jesse Cohen/Investing.com)Stock MarketsJun 13, 2021 09:24AM ET
www.investing.com/analysis/1-stock-to-buy-1-to-dump-when-markets-open-jabil-vertex-pharmaceuticals-200585762
1 Stock To Buy, 1 To Dump When Markets Open: Jabil, Vertex Pharmaceuticals
By Investing.com (Jesse Cohen/Investing.com)   |  Jun 13, 2021 09:24AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Stocks on Wall Street ended the week on a high note, with indexes looking past inflation worries as most major averages closing within sight of their recent records. The NASDAQ Composite posted a weekly gain of 1.9% to record its fourth straight winning week, boosted by a rally in the mega-cap tech stocks.

The benchmark S&P 500, meanwhile, tacked on 0.4% to mark its third winning week in a row. The blue-chip Dow Jones Industrial Average, however, underperformed, falling 0.8% over the same timeframe, as investors rotated out of value stocks.

 

Dow, SP, NASDAQ Daily Charts
Dow, SP, NASDAQ Daily Charts

Between the Federal Reserve’s key monetary policy meeting, as well as more important economic data, including the latest retail sales report, the week ahead is expected to be a busy one on Wall Street.

Regardless of which direction the market takes, below we highlight one stock likely to be in demand and another which could see further downside. 

Remember though, our timeframe is just for the upcoming week.

Stock To Buy: Jabil

Formerly known as Jabil Circuit (NYSE:JBL), Jabil will be in focus this week, as investors await the latest financial results from one of the world’s leading electronic manufacturing services (EMS) providers.

The St. Petersburg, Florida-based company—best known for supplying components for iPhones and other Apple (NASDAQ:AAPL) devices—has thrived this year amid soaring demand for its products and services.

Year-to-date, Jabil, which operates 100 plants in 30 countries and has more than 260,000 employees worldwide, has seen its stock rise by 36%. It has nearly doubled over the past 12 months, gaining around 90% year-over-year.

After reaching a fresh 52-week high of $58.28 on Friday, JBL stock closed the session at $57.89, a level not seen since November 2000. At current levels, the manufacturing services company has a market cap of about $8.6 billion.

JBL Daily Chart
JBL Daily Chart

 

JBL Monthly Chart
JBL Monthly Chart

Jabil, which crushed expectations for earnings and revenue in the last quarter, is scheduled to report fiscal third quarter numbers ahead of the U.S. market open on Thursday.

Consensus expectations call for earnings per share of $1.04, jumping a whopping 181% from EPS of $0.37 in the year-ago period. Meanwhile, revenue is expected to improve almost 10% year-over-year to $6.95 billion.

Beyond the top- and bottom-line figures, investors are hoping Jabil’s management will maintain its upbeat outlook for the remainder of the year, after boosting its guidance in the previous quarter, citing strong secular tailwinds and accelerated momentum in many of its end markets.

Jabil engages mostly in design engineering, manufacturing, and supply chain services for the EMS and consumer industries. It also provides materials technology services, such as plastics, metals, automation, and tooling.

The manufacturing contractor’s clients span numerous industries, including consumer products, computing, storage, networking and telecommunications, healthcare, defense, aerospace, automotive, as well as clean technology, and instrumentation.

Stock To Dump: Vertex Pharmaceuticals 

Investors may want to stay away from shares of Vertex Pharmaceuticals (NASDAQ:VRTX) this week after the biotech firm said it would abandon any further development of an experimental drug designed to treat a rare genetic disease—AAT Deficiency (AATD)—which can lead to liver and lung disease.

The company said late last week that the Phase 2 trial of VX-864 met its primary endpoint, however the results are not likely to lead to substantial patient benefit.

The setback does not bode well for Vertex, which will now likely fall further behind rivals Arrowhead Pharmaceuticals (NASDAQ:ARWR), and Takeda Pharmaceutical (NYSE:TAK) in the race to develop treatment for the rare genetic disorder.

Vertex's next candidate for the treatment of AATD will likely not be tested on humans until 2022 at the earliest.

VRTX Daily Chart
VRTX Daily Chart

Vertex shares have cratered nearly 18% year-to-date, significantly underperforming the comparable returns of both the Dow and the S&P 500 over the same timeframe.

VRTX stock—which is now roughly 37% below its all-time high of $306.08 touched in July 2020—closed Friday’s session at a more than two-year low of $193.02, earning the Boston, Massachusetts-based biotech firm a valuation of about $50 billion.

From a technical standpoint, VRTX stock is now firmly below its 50-day, 100-day, and 200-day moving averages, which usually signals more selling pressure ahead.

VRTX MDAs
VRTX MDAs

Taking this into consideration, Vertex shares look set to remain on the backfoot in the coming days, with investors becoming increasingly concerned by the drug-maker’s future prospects as it struggles in its attempt to diversify its offerings beyond its core cystic fibrosis drugs.

1 Stock To Buy, 1 To Dump When Markets Open: Jabil, Vertex Pharmaceuticals
 

Related Articles

1 Stock To Buy, 1 To Dump When Markets Open: Jabil, Vertex Pharmaceuticals

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (7)
Henry Moradpour
Henry Moradpour Jun 14, 2021 9:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Just inverse what he says trust me
Kelly Brimmer
Kelly Brimmer Jun 14, 2021 9:11AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
You nailed it Henry. Jesse must be shorting jbl.
elliot trach
elliot trach Jun 14, 2021 2:52AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Very odd, two people with exact same wording in favorable comment on VRTX. Very strange.
Jeff Page
Jeff Page Jun 13, 2021 11:58PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Can you do a piece on ASO. SMID CAP that has growth and knock out earnings.
Jesse Cohen
Jesse Cohen Jun 13, 2021 11:58PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Jaycom Osaruyiwmen
Jaycom Osaruyiwmen Jun 13, 2021 2:30PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Great analysis and good insight. thanks Jesse.
Garrett Millard
Garrett Millard Jun 13, 2021 2:11PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$VRTX released even more incredibly impressive CTX001 data the same day lmfao… no one was concerned about VX-864. You are out of your comfort zone here Jesse
Peter Blocked
Peter Blocked Jun 13, 2021 2:11PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Vertex is a hard sell. Sell while there is still time!
Rana Rihan
Rana Rihan Jun 13, 2021 2:05PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Nour Durra
Nour Durra Jun 13, 2021 12:21PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
we also buy AMC and GME
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email